European Journal of Dermatology
MENUCutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: an uncommon adverse effect? Volume 27, issue 6, November-December 2017
Figures
1 Section of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy
2 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, and Center for Rare Immunological and Cardiovascular Diseases, Behçet Center and Lupus Clinic, AOU Careggi, Florence, Italy
3 Nephrology Unit, Parma University Hospital, Parma, Italy
4 Division of Pathology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy
- DOI : 10.1684/ejd.2017.3143
- Page(s) : 667-8
- Published in: 2017
Rituximab is an unconjugated chimaeric monoclonal IgG1κ antibody that binds the transmembrane protein CD20, exclusively expressed by mature B cells. Initially developed for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukaemia, it has also been approved for the treatment of rheumatoid arthritis and for severe forms of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, granulomatosis with polyangiitis, and microscopic polyangiitis (MPA) [1]. We report a patient who [...]